Want to see IN:BALAXI full AI Analyst Report?
Top Page
Balaxi Pharmaceuticals Limited
(BALAXI)
Select Model
Select Model
Rating:44Neutral
Price Target:
₹24.50
▼(-9.46% Downside)
Action:Reiterated
Date:08/30/26
Overall score is weighed down mainly by weak financial performance—especially sustained negative operating/free cash flow and a sharp FY2026 profitability drop—along with bearish technical conditions (price below key moving averages and negative MACD). Valuation provides limited support given the high P/E and no dividend yield data.
Positive Factors
Moderate Leverage
Moderate leverage and an expanding equity base provide financial capacity to support operations and absorb volatility. With debt-to-equity near 0.23, the company is not currently dependent on heavy borrowing, although returns on that capital remain weak.
Negative Factors
Persistent Cash Burn
Negative operating cash flow in FY2025 and FY2026, together with deeply negative free cash flow, shows that reported earnings are not converting into cash. Persistent cash consumption can raise funding needs and restrict reinvestment or working-capital flexibility over coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Moderate Leverage
Moderate leverage and an expanding equity base provide financial capacity to support operations and absorb volatility. With debt-to-equity near 0.23, the company is not currently dependent on heavy borrowing, although returns on that capital remain weak.
Read all positive factors
Balaxi Pharmaceuticals Limited (BALAXI) vs. iShares MSCI India ETF (INDA)
Market Cap
₹1.27B
Dividend Yield0.7%
Average Volume (3M)50.16K
Price to Earnings (P/E)52.3
Beta (1Y)1.04
Revenue Growth8.91%
EPS Growth-57.94%
CountryIN
Employees51
SectorGeneral
Sector StrengthN/A
IndustryMedical - Distribution
Share Statistics
EPS (TTM)0.26
Shares Outstanding55,207,500
10 Day Avg. Volume62,310
30 Day Avg. Volume50,165
Financial Highlights & Ratios
PEG Ratio-0.64
Price to Book (P/B)0.34
Price to Sales (P/S)0.31
P/FCF Ratio-1.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Balaxi Pharmaceuticals Limited Business Overview & Revenue Model
Company Description
Balaxi Pharmaceuticals Limited, through its entity Balaxi Ventures Ltd., primarily operates as an international wholesale distributor specializing in pharmaceuticals, various food items, and hardware supplies. The company's corporate base is situa...
How the Company Makes Money
Balaxi Pharmaceuticals Limited primarily makes money by generating revenue from the sale of pharmaceutical products that it commercializes (i.e., markets and distributes) across its target markets. Its key revenue stream is product sales to custom...
Balaxi Pharmaceuticals Limited Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
68
Positive
Cash Flow
22
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.73B | 2.89B | 2.41B | 3.36B | 2.79B |
| Gross Profit | 1.14B | 1.27B | 1.13B | 1.34B | 837.91M |
| EBITDA | 74.45M | 305.64M | 456.59M | 603.82M | 560.20M |
| Net Income | 14.17M | 250.70M | -23.87M | 459.63M | 476.58M |
Balance Sheet | |||||
| Total Assets | 3.37B | 3.10B | 2.58B | 2.40B | 1.76B |
| Cash, Cash Equivalents and Short-Term Investments | 145.59M | 394.00M | 622.91M | 282.17M | 71.93M |
| Total Debt | 576.49M | 534.25M | 194.04M | 133.06M | 36.38M |
| Total Liabilities | 879.53M | 786.06M | 569.79M | 567.89M | 633.07M |
| Stockholders Equity | 2.49B | 2.32B | 2.01B | 1.83B | 1.13B |
Cash Flow | |||||
| Free Cash Flow | -451.69M | -589.01M | 32.97M | -89.05M | 68.00M |
| Operating Cash Flow | -82.44M | -377.82M | 48.66M | 60.75M | 341.44M |
| Investing Cash Flow | -207.79M | -217.64M | -10.46M | -105.65M | -284.48M |
| Financing Cash Flow | 41.82M | 366.55M | 302.54M | 255.13M | -1.63M |
Balaxi Pharmaceuticals Limited Technical Analysis
Neutral
27.06
Price Trends
23.76
Negative
24.36
Negative
24.48
Negative
Market Momentum
-0.08
Positive
49.83
Neutral
21.89
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BALAXI, the sentiment is Neutral. The current price of 27.06 is above the 20-day moving average (MA) of 23.38, above the 50-day MA of 23.76, and above the 200-day MA of 24.48, indicating a neutral trend. The MACD of -0.08 indicates Positive momentum. The RSI at 49.83 is Neutral, neither overbought nor oversold. The STOCH value of 21.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:BALAXI.
Balaxi Pharmaceuticals Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | ₹1.64B | 11.60 | ― | 0.70% | 4.29% | 2.40% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ₹1.22B | 35.92 | ― | ― | 0.46% | -83.31% | |
52 Neutral | ₹1.83B | -7.75 | ― | 0.40% | 8.84% | -285.42% | |
49 Neutral | ₹1.62B | 22.17 | ― | 1.19% | 13.51% | -14.80% | |
44 Neutral | ₹1.27B | 52.33 | ― | 0.70% | 8.91% | -57.94% |
* General Sector Average
IN:BALAXI
Balaxi Pharmaceuticals Limited
23.55
-23.22
-49.65%
IN:ALPA
Alpa Laboratories Limited
60.05
-34.58
-36.54%
IN:BALPHARMA
Bal Pharma Limited
100.27
17.23
20.75%
IN:PAR
Par Drugs and Chemicals Limited
136.60
23.93
21.24%
IN:NATCAPSUQ
Natural Capsules Limited
172.20
-73.85
-30.01%
IN:BI
Bilcare Ltd
109.14
18.94
21.00%
Balaxi Pharmaceuticals Limited Corporate Events
Balaxi Pharma Shareholders Clear Second Term for Independent Director Akshita Ostwal
Aug 24, 2026
Balaxi Pharmaceuticals Limited has announced that its shareholders approved the re-appointment of Ms. Akshita Ostwal as an Independent Director at the company’s 83rd Annual General Meeting held on 24 August 2026. Her second term on the board...
Exchange Seeks Clarification from Balaxi Pharmaceuticals on March 2026 Results
Jun 24, 2026
The stock exchange has requested clarification from Balaxi Pharmaceuticals Limited regarding its financial results for the quarter ended 31 March 2026, specifically in relation to compliance with Regulation 33 of the SEBI (Listing Obligations and ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.